Texas Roadhouse earnings missed by $0.05, revenue topped estimates
DUBLIN - Uniphar PLC, a global pharmaceutical services company, disclosed transactions involving its top executives as part of its Executive Restricted Share Plan. Gerard Rabbette, CEO, and Timothy Dolphin, CFO, engaged in dealings with ordinary shares on February 25, 2025, as reported by the company.
The transactions, which took place on Euronext (EPA:ENX) Dublin, involved the purchase and sale of Uniphar’s ordinary shares at a price of €2.60 per share. Gerard Rabbette’s dealings resulted in no net change to his beneficial holding, with both the purchase and sale of 382,548 ordinary shares. The shares were purchased by Intertrust Trustee (Ireland) Limited, acting as trustee of the Uniphar plc Employee Benefit Trust (Ireland), and held on trust for Rabbette.
In contrast, Timothy Dolphin’s transactions led to a net increase in his beneficial holding of Uniphar shares. Dolphin purchased 255,031 ordinary shares and sold 200,000, resulting in an increase of 55,031 shares beneficially held by him. Similar to Rabbette’s case, the shares were purchased by Intertrust Trustee (Ireland) Limited on trust for Dolphin under the company’s share plan.
These transactions are required to be disclosed under Article 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation). The regulatory framework aims to ensure transparency and maintain investor confidence in the financial markets.
The information regarding these transactions has been provided by RNS, the news service of the London Stock Exchange (LON:LSEG), and is based on a press release statement. RNS is authorized by the Financial Conduct Authority in the United Kingdom (TADAWUL:4280) as a Primary Information Provider. Terms and conditions related to the use and distribution of this information may apply.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.